Read the counter-case
On this page
Maharashtra FDA cancels Cipla unit's Pune warehouse licences
Maharashtra FDA cancelled Cipla Pharma & Life Sciences Ltd's Pune warehouse sale and distribution licences on October 1 over Reactin Plus packaging claims and deficiencies in storage, expired-medicine handling, documentation and inventory management.
The numbers
Figures from ET Small Business,
| Revised show-cause notice: | September 4 |
|---|---|
| Company written reply: | September 11 |
| Personal hearing: | September 21 |
| Earlier FDA action: | August 27 |
The counter-case
The case against this reading — not reported by the source.
The cancellation could interrupt local supply, raise remediation costs and undermine confidence in the subsidiary’s distribution controls. Storage and expired-medicine handling deficiencies would be more consequential if repeated elsewhere. However, a single warehouse action does not establish a company-wide sales restriction or manufacturing ban.